/ Label notes
What the approved labels actually say.
The most common question in this category is what happens when a medicine is taken alongside something else. For compounds with an approved FDA label, that question has a published answer, and this is it: each note restates a numbered section of the label, with the section named so you can check it against the source yourself.
/ Read this first
This is a reference, not a checker, and the difference is the whole point.
A checker implies it looked at everything you take and cleared it. This does not do that and cannot. Nothing here is ranked by severity, scored, or turned into advice of our own, because the label does not rank these and neither may we.
Most compounds people track have no approved label at all, so they are absent from this page entirely. Absence means nothing was transcribed, never that a combination is safe. These questions belong with the prescriber who knows your full medication list.
/ By compound
Compounds with an approved label.
/ By topic
The same notes, grouped by what they are about.
Grouping is the one piece of arrangement here, and it is presentational: it puts two labels that describe the same phenomenon side by side. Drawing a conclusion from that overlap is your step to take with a clinician, not ours to take for you.
Other oral medications
6 labelsDulaglutide delays gastric emptying and the label states it has the potential to reduce the rate at which oral medicines taken at the same time are absorbed. The label notes the delay is largest after the first dose and lessens with later ones.
The label states exenatide may affect the absorption of orally administered medicines.
Liraglutide causes a delay in gastric emptying. The label notes it did not affect absorption of the medicines tested to any clinically relevant degree, but still advises caution with oral medicines taken at the same time.
Pramlintide slows gastric emptying. Where rapid onset of an oral medicine matters, the label says to give it at least 1 hour before or 2 hours after pramlintide.
Semaglutide delays gastric emptying. The label says to consider increased clinical or laboratory monitoring when it is taken alongside oral medicines that have a narrow therapeutic index or that need monitoring.
Tirzepatide delays gastric emptying and the label states it has the potential to affect how oral medicines taken at the same time are absorbed, advising caution.
Insulin and insulin secretagogues
5 labelsThe label reports the risk of hypoglycemia is increased when exenatide is used with an insulin secretagogue such as a sulfonylurea, or with insulin, and says to consider reducing the dose of those when starting.
The label reports an increased risk of hypoglycemia, including severe hypoglycemia, in adults also taking an insulin secretagogue or insulin, and says a dose reduction of those may be necessary.
The label reports an increased risk of severe hypoglycemia, particularly in type 1 diabetes, and directs that mealtime insulin be reduced by 50% when pramlintide is started.
Taken with insulin or an insulin secretagogue such as a sulfonylurea, the label reports an increased risk of hypoglycemia, including severe hypoglycemia, and notes that reducing the dose of the insulin or secretagogue may be necessary.
The label says to consider reducing the dose of a concomitant insulin secretagogue such as a sulfonylurea, or of insulin, when starting tirzepatide, to reduce the risk of hypoglycemia.
Mixing in one syringe
1 labelThe label states pramlintide and insulin must not be mixed in the same syringe and must be given as separate injections, because mixing alters the pharmacokinetics of both.
Warfarin
1 labelThe label carries postmarketing reports of increased INR, sometimes with bleeding, in people also taking warfarin, and says to monitor INR frequently until stable when exenatide is started or changed.
Transcribed from openFDA label documents. Educational reference only, not medical advice, and not a substitute for the judgement of the clinician who knows what you take.